Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review

References

• Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013;189:1214–1221.
   PubMed Web of Science ®Google Scholar
• Rink M, Ehdaie B, Cha EK, et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol. 2012;62:677–684.
   PubMed Web of Science ®Google Scholar
• Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35:379–387.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009;103:307–311.
   PubMed Web of Science ®Google Scholar
• Favaretto RL, Shariat SF, Savage C, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int. 2012;109:77–82.
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Babjuk M, Compérat E, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111–122.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ) - 2019 update. Eur Urol. 2019;76:639–657.
   PubMed Web of Science ®Google Scholar
• Sevcenco S, Ponhold L, Heinz-Peer G, et al. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urol Oncol. 2014;32:1166–1171.
   Web of Science ®Google Scholar
• Voskuilen CS, Schweitzer D, Jensen JB, et al. Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma. Eur Urol Oncol. 2020;3:73–79.
   PubMed Web of Science ®Google Scholar
• Paik ML, Scolieri MJ, Brown SL, et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693–1696.
   Web of Science ®Google Scholar
• Crozier J, Papa N, Perera M, et al. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol. 2019;37:667–690.
   Web of Science ®Google Scholar
• Nishimura K, Hida S, Nishio Y, et al. The validity of magnetic resonance imaging (MRI) in the staging of bladder cancer: comparison with computed tomography (CT) and transurethral ultrasonography (US). Jpn J Clin Oncol. 1988;18:217–226.
   PubMed Web of Science ®Google Scholar
• Vali R, Loidl W, Pirich C, et al. Imaging of prostate cancer with PET/CT using 18F-Fluorocholine. Am J Nucl Med Mol Imaging. 2015;5:96–108.
   PubMed Web of Science ®Google Scholar
• Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745–3749.
   PubMed Web of Science ®Google Scholar
• Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–2095.
   PubMed Web of Science ®Google Scholar
• Cervino AR, Cuppari L, Reccia P, et al. The role of PET/CT in the evaluation of patients with urothelial cancer: a systematic review and meta-analysis. Clin Transl Imaging. 2018;6:77–89.
   Web of Science ®Google Scholar
• Abufaraj M, Dalbagni G, Daneshmand S, et al. The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol. 2018;73:543–557.
   Web of Science ®Google Scholar
• Zhang H, Xing W, Kang Q, et al. Diagnostic value of [18 F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis. Tumour Biol. 2015;36:3209–3214.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Yoshida S, Komai Y, et al. Clinical value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in upper tract urothelial carcinoma: impact on detection of metastases and patient management. Urol Int. 2016;96:65–72.
   Web of Science ®Google Scholar
• Asai S, Fukumoto T, Tanji N, et al. Fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of upper urinary tract urothelial carcinoma. Int J Clin Oncol. 2015;20:1042–1047.
   Web of Science ®Google Scholar
• Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009;27:4314–4320.
   PubMed Web of Science ®Google Scholar
• Apolo AB, Riches J, Schöder H, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28:3973–3978.
   Web of Science ®Google Scholar
• Lodde M, Lacombe L, Friede J, et al. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int. 2010;106:658–663.
   Web of Science ®Google Scholar
• Rouanne M, Girma A, Neuzillet Y, et al. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Eur J Surg Oncol. 2014;40:1724–1730.
   PubMed Web of Science ®Google Scholar
• Hitier-Berthault M, Ansquer C, Branchereau J, et al. 18F-fluorodeoxyglucose positron emission tomography–computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: A prospective study. Int J Urol. 2013;20:788–796.
   Web of Science ®Google Scholar
• Girard A, Rouanne M, Taconet S, et al. Integrated analysis of (18)F-FDG PET/CT improves preoperative lymph node staging for patients with invasive bladder cancer. Eur Radiol. 2019;29:4286–4293.
   PubMed Web of Science ®Google Scholar
• Drieskens O, Oyen R, Van Poppel H, et al. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005;32:1412–1417.
   PubMed Web of Science ®Google Scholar
• Swinne G, Maes A, Pottel H, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57:641–647.
   Web of Science ®Google Scholar
• Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 2014;114:389–395.
   PubMed Web of Science ®Google Scholar
• Aljabery F, Lindblom G, Skoog S, et al. PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer. BMC Urol. 2015;15:87.
   Web of Science ®Google Scholar
• Pichler R, De Zordo T, Fritz J, et al. Pelvic lymph node staging by combined (18)F-FDG-PET/CT imaging in bladder cancer prior to radical cystectomy. Clin Genitourin Cancer. 2017;15:e387–e395.
   PubMed Web of Science ®Google Scholar
• Dason S, Wong NC, Donahue TF, et al. Utility of routine preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography in identifying pathological lymph node metastases at radical cystectomy. J Urol. 2020;204:254–259.
   Web of Science ®Google Scholar
• Vind-Kezunovic S, Bouchelouche K, Ipsen P, et al. Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and 18F-fluorodeoxyglucose positron emission tomography/computed tomography: results from a high-volume centre including long-term follow-up. Eur Urol Focus. 2019;5:90–96.
   Google Scholar
• Jadvar H, Quan V, Henderson RW, et al. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol. 2008;13:42–47.
   PubMed Web of Science ®Google Scholar
• Yang Z, Pan L, Cheng J, et al. Clinical value of whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of metastatic bladder cancer. Int J Urol. 2012;19:639–644.
   Web of Science ®Google Scholar
• Öztürk H, Karapolat I. Efficacy of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography in restaging muscle-invasive bladder cancer following radical cystectomy. Exp Ther Med. 2015;9:717–724.
   Web of Science ®Google Scholar
• Soubra A, Hayward D, Dahm P, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol. 2016;34:1229–1237.
   PubMed Web of Science ®Google Scholar
• Jeong IG, Hong S, You D, et al. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Ann Surg Oncol. 2015;22:3150–3156.
   PubMed Web of Science ®Google Scholar
• Jensen TK, Holt P, Gerke O, et al. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol. 2011;45:122–128.
   PubMed Web of Science ®Google Scholar
• Lu YY, Chen JH, Liang JA, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81:2411–2416.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Baumann GS, Baum RP. PSMA diagnostics and treatments of prostate cancer become mature. Clin Transl Imaging. 2018;6:145–148.
   PubMed Web of Science ®Google Scholar
• Corfield J, Perera M, Bolton D, et al. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36:519–527.
   Web of Science ®Google Scholar
• Kim SJ, Lee SW, Ha HK. Diagnostic performance of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging in newly diagnosed intermediate to high-risk prostate cancer patients: a systematic review and meta-analysis. Urol Int. 2019;102:27–36.
   Web of Science ®Google Scholar
• Shvarts O, Han KR, Seltzer M, et al. Positron emission tomography in urologic oncology. Cancer Control. 2002;9:335–342.
   PubMedGoogle Scholar
• Mertens LS, Bruin NM, Vegt E, et al. Catheter-assisted 18F-FDG-PET/CT imaging of primary bladder cancer: a prospective study. Nucl Med Commun. 2012;33:1195–1201.
   Web of Science ®Google Scholar
• Li Y, Diao F, Shi S, et al. Computed tomography and magnetic resonance imaging evaluation of pelvic lymph node metastasis in bladder cancer. Chin J Cancer. 2018;37:3.
   PubMedGoogle Scholar